News & Updates
Filter by Specialty:
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
Omalizumab scores in the NIH*-sponsored phase III OUtMATCH** trial, increasing the threshold for an allergic reaction to peanut and other common food allergens in children and adults with multiple food allergies.
OUtMATCH: Omalizumab gains FDA nod for IgE-mediated food allergies
05 Mar 2024
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
01 Mar 2024
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
29 Feb 2024
Contraceptives ease IBD symptoms but induce intestinal inflammation in women
Women with inflammatory bowel disease (IBD) who use hormonal contraceptives (HCs) appear to be less likely to experience IBD-related symptoms but are more likely to have intestinal inflammation over a year, reports a study.